Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for relapsing Clostridium difficile infection
NCT02743234Phase 3Completed
- Sponsor
- Aarhus University
- Start
- Apr 2016
- Primary completion
- Feb 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of allogeneic fecal microbiota in Clostridium difficile infection (CDI), sponsored by Aarhus University. Primary endpoint: Global resolution (clinical resolution AND negative Clostridium difficile PCR test) at 8 weeks. Started Apr 2016; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT02743234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743234.